News

Xanodyne pharmaceuticals has received the FDA approval for its Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilising

Cadence Pharmaceuticals has announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) goal date for its priority review of the New Drug Application (NDA)

NicOx has reported that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor (atorvastatin), has met its primary and secondary objectives. The primary top-line results

TET Systems has reported that TET Systems and Novo Nordisk have signed a license agreement allowing the Hagedorn Research Institute (HRI), a research institute within Novo Nordisk, the

“Our year-to-date revenues of CAD17.6 million are slightly below last year due to reduced volume in our Bioanalytical division. We have had an unprecedented number of cancellations and

Emergent BioSolutions has completed the acquisition of a 55,000 square foot manufacturing facility from MdBio foundation and the land on which the facility stands from the city of

Esperion Therapeutics has initiated a Phase I clinical study for ETC-1002, the company’s novel small molecule compound designed to beneficially regulate the levels of plasma lipids and lipoproteins.

Ipsen has reported that the French Regulatory Authorities (AFSSAPS) have granted the marketing authorisation to the 6-month sustained-release formulation of Decapeptyl (triptorelin embonate1 22.5 mg) for the treatment

Axelar has reported that promising data from the ongoing Phase I/II clinical trial concerning their lead anticancer product AXL1717, is expected to be presented at the AACR-NCI-EORTC International